ArticleBMC family practice2020
Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients.
Article in BMC family practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Barriers and enablers to deprescribing of older adults and their caregivers: a systematic review and meta-synthesis.European geriatric medicine · 2023Pooled it
- GP perspectives on a computer-assisted strategy to support PPI deprescribing: a qualitative study.Scientific reports · 2026Trial
- Efficacy of a computer based discontinuation strategy to reduce PPI prescriptions: a multicenter cluster-randomized controlled trial.Scientific reports · 2023Trial
- Patients' perspectives on deprescribing in swedish primary care: an exploratory survey study.Scandinavian journal of primary health care · 2026Article
- Long-Term Proton Pump Inhibitor Therapy Is Common Among Older Adults: An 8-Year Finnish Nationwide Register Study.Drugs & aging · 2026Article
- Appropriate Use of Proton Pump Inhibitors in Older Adults: Concerns and Solutions.Drugs & aging · 2026Review
- Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co-Design Approach With General Practitioners and Patients.Basic & clinical pharmacology & toxicology · 2025Article
- Improving the feasibility of deprescribing proton pump inhibitors: GPs' insights on barriers, facilitators, and strategies.Frontiers in pharmacology · 2024Article
- (De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database.BMC primary care · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeprescribing of proton pump inhibitors (PPIs) can be considered in situations where the drug may no longer be necessary; however, this requires a careful discussion between patients and healthcare providers, often general practitioners (GPs). The aim of our study was to explore how GPs discuss PPI deprescribing with patients and compare that to how older patients would like to discuss this decision.
methodsWe conducted a qualitative study using semi-structured interviews with GPs (n = 11) and patients aged ≥65 years who were taking PPIs (n = 4). Analysis of interviews was based on systematic text condensation.
resultsWe identified four main themes: (1) Reasons PPI deprescribing comes up, (2) Considering PPI deprescribing, (3) Discussion topics, and (4) Incorporating patient preferences into PPI deprescribing decisions. We found that PPI deprescribing often comes up during consultations for other problems or due to concern about medication burden in general. GPs discussed topics related to symptom control, such as the possibility of rebound symptoms, the need to taper PPIs, and what to do if symptoms returned. This aligned with what patients felt was important to discuss. Some GPs routinely incorporated patient preferences into decisions, whereas others did not.
conclusionWhen discussing PPI deprescribing, the GPs in our study generally focused on topics related to symptom control. There was variability in how and if patient preferences were discussed. Greater focus may be needed on developing mechanisms to elicit and incorporate patient preferences into PPI deprescribing decisions. Future research could also explore more systematic approaches to reassess ongoing PPI use in an effort to curb unnecessary long-term use of PPIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.